泛自闭症障碍治疗药物市场：依药物类型、年龄层、通路和地区划分

据估计，2026 年泛自闭症障碍治疗市场价值为 23.9 亿美元，预计到 2033 年将达到 37.61 亿美元，2026 年至 2033 年的复合年增长率为 6.7%。

自闭症，科学上称为泛自闭症障碍（ASD），是一种复杂的神经系统疾病，其特征包括社交技能障碍、重复性行为以及语言和非语言沟通障碍。在ASD治疗市场运作的主要企业正致力于进行广泛的研究、开发和临床试验，以推出新药。例如，2019年2月，施维雅製药（Servier Laboratories）和NeuroChlore公司宣布启动一项评估布Bumetanide）治疗ASD儿童的3期临床试验。Bumetanide通常用于治疗体液储存（水肿）和高血压。

市场动态

全球泛自闭症障碍（ASD）盛行率的不断上升预计将推动ASD药物市场的成长。例如，根据Our World in Data 2017年发布的数据，截至2016年，全球约有6,200万人患有ASD。此外，其中男性患者不足5000万。在这6,200万ASD患者中，约有1,800万人仅患有自闭症，而4,400万人患有亚斯伯格症候群或其他频谱障碍。

然而，监管机构对产品核可和药品销售的严格规定和持续监督可能会阻碍泛自闭症障碍治疗市场的成长。例如，2017年5月，美国食品药物管理局（FDA）暂停了总部位于路易斯安那州的药品和营养补充剂生产商Pick and Pay Inc. Cili Minerals的运营，原因是该公司被发现虚假宣传其产品可以治愈自闭症。

本次调查的主要特点

• 本报告对泛自闭症障碍治疗市场进行了详细分析，涵盖了预测期（2019-2027 年）内的市场规模和复合年增长率（%），以 2018 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数介绍了全球泛自闭症障碍治疗药物市场主要企业的概况：公司概况、财务表现、产品系列、地理扩张、分销策略、关键发展和策略。
• 本报告的研究结果将使企业负责人和经营团队能够就未来的产品发布、政府措施、技术升级、市场扩张和行销策略做出明智的决策。
• 这份全球泛自闭症障碍治疗市场报告对行业内的各种利益相关者都很有用，包括泛自闭症障碍治疗市场的投资者、产品製造商、经销商、相关人员、研究和咨询公司、新参与企业和金融分析师。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场概览

• 报告概述
  • 市场定义和范围
• 执行摘要

第三章 市场动态、监理及趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准情况
• PEST分析
• 波特分析
• 市场机会
• 法规环境
• 重大进展
• 产业趋势

4. 2020-2033年全球泛自闭症障碍治疗药物市场（依药物类型划分）

• Aripiprazole
• Risperidone
• 褪黑素
• CM-AT
• Bumetanide
• Balovaptan

5. 2020-2033年全球泛自闭症障碍治疗市场（依年龄层划分）

• 儿童
• 成人

6. 2020-2033年全球泛自闭症障碍治疗药物市场（依通路划分）

• 医院药房
• 零售药房
• 网路药房

7. 2020-2033年全球泛自闭症障碍治疗市场（按地区划分）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第八章 竞争情势

• F. Hoffmann-La Roche AG
• Neurim Pharmaceuticals, Inc.
• Yamo Pharmaceuticals LLC
• Servier Laboratories Ltd.
• Otsuka Holdings Co. Ltd.
• Curemark LLC
• Oryzon Genomics SA
• GW Pharmaceuticals Plc.
• Teva Pharmaceutical Industries Ltd.
• Zynerba Pharmaceuticals Inc.
• STALICLA SA
• Novartis AG
• Pfizer, Inc.
• Bristol Myers Squibb

第九章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十章 参考文献与调查方法

• 参考
• 调查方法
• 关于本公司

Autism Spectrum Disorder Therapeutics Market is estimated to be valued at USD 2,390 Mn in 2026 and is expected to reach USD 3,761 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study

• This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2027, considering 2018 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Aripiprazole
  • Risperidone
  • Melatonin
  • CM-AT
  • Bumetanide
  • Balovaptan
• Age Group Insights (Revenue, USD Mn, 2026 - 2033)
  • Child
  • Adult
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • F. Hoffmann-La Roche AG
  • Neurim Pharmaceuticals, Inc.
  • Yamo Pharmaceuticals LLC
  • Servier Laboratories Ltd.
  • Otsuka Holdings Co. Ltd.
  • Curemark LLC
  • Oryzon Genomics S.A.
  • GW Pharmaceuticals Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Zynerba Pharmaceuticals Inc.
  • STALICLA SA
  • Novartis AG
  • Pfizer, Inc.
  • Bristol Myers Squibb

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Autism Spectrum Disorder Therapeutics Market, By Drug Type
  • Global Autism Spectrum Disorder Therapeutics Market, By Age Group
  • Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel
  • Global Autism Spectrum Disorder Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Aripiprazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Risperidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Melatonin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• CM-AT
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Bumetanide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Balovaptan
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Child
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2020 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Neurim Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Yamo Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Servier Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Holdings Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Curemark LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Oryzon Genomics S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GW Pharmaceuticals Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zynerba Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• STALICLA SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us